Phase 2 Breast Cancer Trial, By Invitation NCT07359404 Sponsor: YING FAN Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, By Invitation

NCT07359404
By Invitation Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Adults aged 18 years or older.
  • People with a laboratory-confirmed diagnosis of triple-negative breast cancer (TNBC) that has come back or spread to other parts of the body.
  • People whose cancer has been tested and meets specific definitions of being "triple-negative" (low levels of estrogen and progesterone receptors, and HER2 negative based on standard lab tests), and who have already received at least one treatment for their cancer after it spread.
  • People with a good general level of physical functioning, rated 0 or 1 on a standard medical scale (meaning fully active or able to carry out light work).
  • People with a life expectancy of more than 3 months.
  • People who have at least one area of cancer that can be measured using standard imaging criteria (known as RECIST 1.1).
  • People whose organs (such as liver, kidneys, and bone marrow) are functioning at an adequate level.
  • People who have waited a sufficient amount of time since their last cancer treatment before entering the trial — at least 3 weeks after chemotherapy, or at least 4 weeks after targeted therapy.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have previously been treated with the drugs Sacituzumab Govitecan or Bevacizumab.
  • People with uncontrolled central nervous system involvement (confirm with trial site).
  • People who have another active primary cancer in addition to their breast cancer.
  • People with severe infection, serious heart disease, autoimmune disease, or other health conditions that the treating doctor considers unsuitable for anti-cancer treatment.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 31 July 2026

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
By Invitation
Phase
Phase 2
Sponsor
YING FAN
Registry
ClinicalTrials.gov
Start date
1 April 2024
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progression-Free Survival; Incidence and Severity of Adverse Events (Safety)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov